Urogen Pharma (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from Brokerages

Key Points

• Urogen Pharma has received an average consensus recommendation of "Buy" from eight brokerages, with six analysts rating it a buy and one a strong buy, while the average 12-month price target is approximately $31.43.
• The company reported a quarterly loss per share of ($1.05), which was worse than analysts' expectations but had revenue of $24.22 million, surpassing the consensus estimate.
• Insider trading activity shows that executives have sold a significant number of shares, with a total of 17,833 shares sold in the last 90 days, indicating potential shifts in confidence among company insiders.

Urogen Pharma (NASDAQ:URGN - Get Free Report) has been given an average rating of "Buy" by the eight brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $31.4286.

A number of equities analysts have recently commented on URGN shares. HC Wainwright dropped their price objective on Urogen Pharma from $50.00 to $40.00 and set a "buy" rating on the stock in a research note on Monday. The Goldman Sachs Group set a $16.00 price objective on Urogen Pharma and gave the stock a "neutral" rating in a research note on Friday, June 13th. D. Boral Capital reiterated a "buy" rating and issued a $25.00 price objective on shares of Urogen Pharma in a research note on Tuesday, August 5th. Scotiabank restated an "outperform" rating on shares of Urogen Pharma in a research note on Friday, June 13th. Finally, Guggenheim restated a "buy" rating and set a $30.00 price target (up from $15.00) on shares of Urogen Pharma in a research note on Friday, June 13th.

Urogen Pharma Stock Performance

Urogen Pharma stock opened at $19.20 on Wednesday. The business's 50-day simple moving average is $14.61 and its 200-day simple moving average is $11.46. The firm has a market capitalization of $888.27 million, a PE ratio of -5.78 and a beta of 1.12. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $21.01.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($1.05) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.23). The business had revenue of $24.22 million during the quarter, compared to the consensus estimate of $23.06 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%. Research analysts forecast that Urogen Pharma will post -3.12 earnings per share for the current year.

Insider Activity

In related news, General Counsel Jason Drew Smith sold 7,522 shares of the business's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $19.14, for a total transaction of $143,971.08. Following the transaction, the general counsel directly owned 41,492 shares in the company, valued at $794,156.88. The trade was a 15.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Mark Schoenberg sold 5,162 shares of the company's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $7.37, for a total value of $38,043.94. Following the completion of the sale, the insider owned 153,378 shares in the company, valued at approximately $1,130,395.86. This represents a 3.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 17,833 shares of company stock worth $280,567 over the last 90 days. Corporate insiders own 4.70% of the company's stock.

Institutional Trading of Urogen Pharma

Several institutional investors have recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Urogen Pharma by 216.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company's stock valued at $48,227,000 after buying an additional 2,983,368 shares in the last quarter. RTW Investments LP boosted its stake in Urogen Pharma by 1.3% in the 4th quarter. RTW Investments LP now owns 3,834,794 shares of the company's stock valued at $40,841,000 after buying an additional 47,447 shares in the last quarter. RA Capital Management L.P. acquired a new stake in Urogen Pharma in the 1st quarter valued at $35,461,000. Vestal Point Capital LP boosted its stake in Urogen Pharma by 32.1% in the 1st quarter. Vestal Point Capital LP now owns 2,152,957 shares of the company's stock valued at $23,812,000 after buying an additional 522,957 shares in the last quarter. Finally, Toronto Dominion Bank acquired a new stake in Urogen Pharma in the 4th quarter valued at $18,628,000. Institutional investors and hedge funds own 91.29% of the company's stock.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.